EVENTS | VIEW CALENDAR
Future looking bright for eClinical solutions
SANTA CLARA, Calif.—Digital transformation is leading the clinical trial industry toward a much-anticipated data-centric approach, according to investment and advisory firm Frost & Sullivan, which forecasts that the global clinical trial data management and eClinical solutions market will exceed $4 billion by 2020 “due to the increased need for digital continuity, thereby driving unparalleled transparency and efficiency throughout the clinical development lifecycle.”
The Frost & Sullivan report, “Growth Opportunities in the Clinical Trial Data Management and eClinical Solutions Market, Forecast to 2020,” evaluates and discusses market projections, key trends, technology life cycle (adoption rate vs. maturity), key implementation challenges and growth opportunities. The research scope includes select high-growth clinical IT systems such as electronic data capture (EDC), randomization and trial supply management (RTSM), clinical trials management systems (CTMS), electronic clinical outcome assessment (eCOA), biostatistics solutions and trial planning and safety solutions. Finally, the analysis provides industry best practices and strategic imperatives for key clinical trial industry stakeholders such as pharmaceutical sponsors, clinical research organizations (CROs), sites and technology providers. Further information on the report can be found at http://frost.ly/2b3.
“As the clinical trial industry transitions towards future biomarker-based targeted therapeutics and adaptive clinical trial models, the need for digital continuity theme has become critical across clinical trials IT framework to drive transparency and efficiency throughout the clinical development lifecycle,” said Kamaljit Behera, transformational health industry analyst at Frost & Sullivan. “Clinical trial IT vendors providing eClinical modular solutions leveraging cloud-based, multi-tenant systems on flexible software-as-a-service pricing models will be more attractive both for CROs and Big Pharma, compared to function-specific point solutions licensing models.”
As the industry seeks to shift towards cost-efficient and patient-centric clinical trial designs, mobile health devices, when integrated with bring-your-own-device (BYOD) platforms, demonstrate the maximum value. Emerging BYOD concepts provide an efficient alternative, according to Frost & Sullivan, as more than 30 percent of eCOA solution costs are associated with the supply of provisioned devices. Multi-modality eCOA solutions supporting BYOD concepts presumably will help pharmaceutical sponsors and CROs to reduce hardware, maintenance and telecom costs, increase flexibility in capturing data and reduce logistics costs.
Further growth opportunity trends include:
“The integration of eClinical platforms with an evolving ecosystem of connected ‘Internet of things’ devices and solutions has the potential to change the process of clinical trials, making them more efficient and cost-effective while accelerating research into new treatments,” observed Behera. “Apart from optimizing the clinical trial IT systems at the backend, vendors need to leverage converging technologies such as artificial intelligence, machine learning, analytics and visualization tools to provide real-time access for the data review process with intuitive user interfaces to improve collaboration among sites, sponsors, CROs and patients.”